Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | FNTA | P49354 | 4/20 | 0.45 |
| ▸ | FNTB | P49356 | 4/20 | 0.45 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4284629 | 1.00 | LMNA (0.48) | LMNAFNTAFNTBPGGT1BTGFBR1 | |
| SCHEMBL29630632 | 0.97 | LMNA (0.46) | LMNAFNTAFNTBPGGT1BTGFBR1 | |
| SCHEMBL30575172 | 0.95 | LMNA (0.48) | LMNAFNTAFNTBPGGT1BCA2 | |
| SCHEMBL29350482 | 0.93 | LMNA (0.43) | LMNAFNTAFNTBPGGT1BCA2 | |
| SCHEMBL30642092 | 0.92 | FNTA (0.48) | FNTAFNTBPGGT1B | |
| SCHEMBL31438607 | 0.90 | PDCD1LG2 (0.42) | LMNAFNTAFNTBPGGT1BTGFBR1 | |
| SCHEMBL29630436 | 0.90 | MME (0.45) | LMNAFNTAFNTBPGGT1BMME | |
| SCHEMBL1157691 | 0.90 | LMNA (0.57) | LMNAFNTAFNTBPGGT1BCA2 | |
| SCHEMBL1157690 | 0.90 | LMNA (0.57) | LMNAFNTAFNTBPGGT1BCA2 | |
| SCHEMBL17823046 | 0.90 | LMNA (0.57) | LMNAFNTAFNTBPGGT1BCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794640-B1 | METHOD FOR RECOMBINANT PRODUCTION OF LABYRINTHOPEPTINS AND FUNCTIONAL DERIVATIVES THEREOF | SANOFI SA (FR) | 2016-07-20 | — | — | EP | disclosed |
| US-20150274787-A1 | METHOD FOR RECOMBINANT PRODUCTION OF LABYRINTHOPEPTINS AND FUNCTIONAL DERIVATIVES THEREOF | SANOFI (FR) | 2015-10-01 | — | — | US | disclosed |
| EP-2794640-A2 | METHOD FOR RECOMBINANT PRODUCTION OF LABYRINTHOPEPTINS AND FUNCTIONAL DERIVATIVES THEREOF | SANOFI (FR) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013092672-A2 | METHOD FOR RECOMBINANT PRODUCTION OF LABYRINTHOPEPTINS AND FUNCTIONAL DERIVATIVES THEREOF | SANOFI (FR) | 2013-06-27 | — | — | WO | disclosed |
| EP-2607374-A1 | Method for recombinant production of labyrinthopeptins and functional derivatives thereof | SANOFI (FR) | 2013-06-26 | — | — | EP | disclosed |
| EP-1861417-B1 | DIMERIC OR MULTIMERIC MICROPROTEINS | BIONTECH AG (DE) | 2013-05-15 | — | — | EP | disclosed |
| US-8258258-B2 | Dimeric or multimeric microproteins | BIONTECH AG (DE) | 2012-09-04 | — | — | US | disclosed |
| US-20090156476-A1 | Dimeric or Multimeric Microproteins | NASCACELL TECHNOLOGIES AG (DE) | 2009-06-18 | — | — | US | disclosed |
| EP-1861417-A2 | DIMERIC OR MULTIMERIC MICROPROTEINS | NascaCell Technologies AG (DE) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006094813-A2 | DIMERIC OR MULTIMERIC MICROPROTEINS | NASCACELL TECHNOLOGIES AG. (DE) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274787-A1 | METHOD FOR RECOMBINANT PRODUCTION OF LABYRINTHOPEPTINS AND FUNCTIONAL DERIVATIVES THEREOF | THOP1, VIP, PRSS12 | LMNA 3517/4885FNTA 247/4885FNTB 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.